Profile data is unavailable for this security.
About the company
International Biotechnology Trust plc is a United Kingdom-based investment trust company. The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies addressing an unmet medical need. The Company seeks to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have growth prospects, with experienced management and strong potential upside through the development and/or commercialization of a pharmaceutical product, device or enabling technology. The Company’s investments may also be made in related sectors, such as medical devices and healthcare services. The Company may invest through equities, index-linked securities and debt securities, cash deposits, money market instruments and foreign currency exchange transactions. SV Health Managers LLP is the Company's alternative investment fund manager (AIFM).
- Revenue in GBP (TTM)12.06m
- Net income in GBP6.81m
- Incorporated1994
- Employees0.00
- LocationInternational Biotechnology Trust6th Floor, 65 Gresham Street,LONDON EC2V 7NQUnited KingdomGBR
- Phone+44 20 7421 7070
- Websitehttps://ibtplc.com/
Profile
| Management group(s) | Schroder Unit Trusts Limited |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GB0004559349 |
| Launch date | 06 May 1994 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
The objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. The company invests in companies that are considered to be good value with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Managed by
| Ailsa Craig, Marek Poszepczynski |
|---|
Management & contract fees
Management fee payable monthly at the rate of 0.9% p.a. of the NAV. The performance fee on the unquoted pool is 20% of net realised gain; performance fee on the quoted pool is 10% of relative outperformance above the sterling-adjusted NBI plus a 0.5% hurdle. Investment Management Agreement is terminable by either party on 12 months’ written notice.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Schroder Real Estate Investment Trst Ltd | 26.11m | -53.92m |
| Baronsmead Second Venture Trust PLC | -1.20m | -6.91m |
| abrdn Diversified Income and Growth PLC | 5.91m | -299.00k |
| International Biotechnology Trust Plc | 12.06m | 6.81m |
| Baillie Gifford UK Growth Trust PLC | 3.13m | 313.00k |
| Aquila European Renewables PLC | -21.56m | -25.59m |
| abrdn European Logistics Income PLC | 36.01m | -70.01m |
| British Smaller Companies VCT plc | 15.21m | 11.99m |
| JPMorgan US Smaller Co Inv Trust PLC | 16.46m | 11.79m |
| Hansa Investment Company Ltd | 34.64m | 30.02m |
| Manchester & London Investment Trust plc | 107.72m | 104.00m |
| Martin Currie Global Portfolio Trust PLC | 28.46m | 26.08m |
| Starwood European Real Estate Financ Ltd | 34.96m | 25.25m |
| Castelnau Group Ltd | 9.98m | -7.78m |
| CC Japan Income and Growth Trust PLC | 41.93m | 38.34m |
| Montanaro European Smllr Cmpns Trst PLC | 32.88m | 29.03m |
